<SEC-DOCUMENT>0001292814-25-002109.txt : 20250516
<SEC-HEADER>0001292814-25-002109.hdr.sgml : 20250516
<ACCEPTANCE-DATETIME>20250515203455
ACCESSION NUMBER:		0001292814-25-002109
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250516
DATE AS OF CHANGE:		20250515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRF S.A.
		CENTRAL INDEX KEY:			0001122491
		STANDARD INDUSTRIAL CLASSIFICATION:	MEAT PACKING PLANTS [2011]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				000000000
		STATE OF INCORPORATION:			D5
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15148
		FILM NUMBER:		25956659

	BUSINESS ADDRESS:	
		STREET 1:		AV DAS NACOES UNIDAS 14401 22ND-25TH
		STREET 2:		FLOORS TORRE A2 VILA GERTRUDES 04794-000
		CITY:			SAO PAULO SP BRAZIL
		STATE:			D5
		ZIP:			00000
		BUSINESS PHONE:		551123225377

	MAIL ADDRESS:	
		STREET 1:		AV DAS NACOES UNIDAS 14401 22ND-25TH
		STREET 2:		FLOORS TORRE A2 VILA GERTRUDES 04794-000
		CITY:			SAO PAULO SP BRAZIL
		STATE:			D5
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRF-BRASIL FOODS S.A.
		DATE OF NAME CHANGE:	20090708

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PERDIGAO SA
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brf20250515_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><FONT STYLE="font-size: 18pt"><B>FORM
6-K<BR>
U.S. SECURITIES AND EXCHANGE COMMISSION<BR>
</B></FONT><B><FONT STYLE="font-size: 10pt">Washington, D.C. 20549</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><B>REPORT OF
FOREIGN PRIVATE ISSUER<BR>
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE<BR>
<FONT STYLE="text-transform: uppercase">SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><B>dated&nbsp;May
15, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><B>Commission
File Number 1-15148</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><FONT STYLE="font-size: 18pt"><B>BRF
S.A.<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(Exact Name as Specified in its Charter)</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><FONT STYLE="font-size: 10pt"><B>N/A</B><BR>
</FONT><FONT STYLE="font-size: 13.5pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">(Translation of Registrant&rsquo;s
Name)</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><B>14401 AV. DAS NACOES UNIDAS 22ND FLOOR</B><BR>
<B>CHAC SANTO ANTONIO 04730 090-S&atilde;o Paulo &ndash; SP, Brazil</B><BR>
<FONT STYLE="font-size: 13.5pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">(Address of principal executive
offices) (Zip code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">Indicate by
check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
Form 40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&nbsp;S-T<BR>
Rule&nbsp;101(b)(1):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation&nbsp;S-T<BR>
Rule&nbsp;101(b)(7):&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">Indicate by
check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;</FONT><FONT STYLE="font-family: Wingdings">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;
No&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">If &ldquo;Yes&rdquo;
is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):&nbsp;Not applicable.</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white">&nbsp;</P>



<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in; background-color: white">This material
includes certain forward-looking statements that are based principally on current expectations and on projections of future events
and financial trends that currently affect or might affect the Company&rsquo;s business, and are not guarantees of future performance.&nbsp;
These forward-looking statements are based on management&rsquo;s expectations, which involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of which are beyond the Company&rsquo;s control and any of which could
cause actual financial condition and results of operations to differ materially fom those set out in the Company&rsquo;s forward-looking
statements.&nbsp; You are cautioned not to put undue reliance on such forward-looking statements.&nbsp; The Company undertakes
no obligation, and expressly disclaims any obligation, to update or revise any forward-looking statements.&nbsp; The risks and
uncertainties relating to the forward-looking statements in this Report on Form 6-K, including Exhibit 1 hereto, include those
described under the captions &ldquo;Forward-Looking Statements&rdquo; and &ldquo;Item 3. Key Information &mdash; D. Risk Factors&rdquo;
in the Company&rsquo;s annual report on Form 20-F for the year ended December 31, 2012.</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white">&nbsp;</P>



<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 1in; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;May&nbsp;15, 2025</FONT></TD>
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRF S.A.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0.7pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Fabio Luis Mendes Mariano</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; padding-right: 0.7pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.7pt">&nbsp;</TD>
    <TD STYLE="width: 7%; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 48%; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Fabio Luis Mendes Mariano</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.7pt">&nbsp;</TD>
    <TD STYLE="padding-right: -9.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="padding-right: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial and Investor Relations Officer</P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white">&nbsp;</P>




<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 13.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; background-color: white"><B>EXHIBIT INDEX</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="width: 84%; border-bottom: Black 1pt solid; padding-right: 0.7pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Description of Exhibit</B></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.7pt; padding-bottom: 6pt"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></A></TD>
    <TD STYLE="padding-right: 0.7pt; padding-bottom: 6pt"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JOINT MATERIAL FACT</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font: 10pt/120% Arial,sans-serif; text-align: center"><IMG SRC="brf202505156k_001.jpg" ALT="A blue and black logo&#10;&#10;AI-generated content may be incorrect." STYLE="height: 92px; width: 227px"></TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font: 10pt/120% Arial,sans-serif; text-align: center"><IMG SRC="brf202505156k_002.jpg" ALT="" STYLE="height: 68px; width: 142px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/120% Arial,sans-serif; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; text-align: center"><B>MARFRIG GLOBAL FOODS S.A.<BR>
</B>Publicly Traded Company<BR>
<FONT STYLE="line-height: 120%">CNPJ/MF n&ordm; 03.853.896/0001-40<BR>
NIRE 35.300.341.031</FONT></TD>
    <TD STYLE="font: 10pt/120% Arial,sans-serif; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; text-align: center"><B>BRF S.A.<BR>
</B>Publicly Traded Company<BR>
CNPJ/MF n&ordm; 01.838.723/0001-27<BR>
NIRE 42.300.034.240</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: center"><B>JOINT MATERIAL FACT</B></P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify"><B>MARFRIG GLOBAL FOODS S.A.</B> (&ldquo;<B>Marfrig</B>&rdquo;)
and <B>BRF S.A.</B> (&ldquo;<B>BRF</B>&rdquo; and, together with Marfrig, the &ldquo;<B>Companies</B>&rdquo;), in compliance with Article
157, Paragraph 4, of Law No. 6,404, dated December 15, 1976 (&ldquo;<B>Brazilian Corporations Law</B>&rdquo;), CVM Resolution No. 44,
dated August 23, 2021 (&ldquo;<B>CVM Resolution 44</B>&rdquo;), and CVM Resolution No. 78, dated March 29, 2022 (&ldquo;<B>CVM Resolution
78</B>&rdquo;), hereby, through this joint material fact, inform their shareholders and the market in general that, on the present date,
the merger Plan of Merger agreement of BRF S.A. Shares by Marfrig Global Foods S.A.&rdquo; (&ldquo;<B>Plan of Merger</B>&rdquo;) was executed,
which sets forth the terms and conditions applicable to the Merger (as defined below).</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify">In addition to the execution of the Plan of Merger,
at meetings held on the date hereof, (i) the Board of Directors of Marfrig (&ldquo;<B>Marfrig Board</B>&rdquo;) approved the convening
of Marfrig's extraordinary general meeting, to be held on the first call on June 18, 2025, at 11:00 a.m. (&ldquo;<B>Marfrig EGM</B>&rdquo;);
and (ii) the Board of Directors of BRF (&ldquo;<B>BRF Board</B>&rdquo;) approved the convening of BRF's extraordinary general meeting,
to be held on the first call on June 18, 2025, at 9:00 a.m. (&ldquo;<B>BRF EGM</B>&rdquo; and, together with the Marfrig EGM, the &ldquo;<B>EGMs</B>&rdquo;),
which will deliberate on the Merger. The information and documents related to the convening of the EGMs, including the management proposal
and the Plan of Merger, will be duly and timely disclosed the Companies, in accordance with the terms and deadlines of applicable legislation
and regulations.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify">Pursuant to the provisions of CVM Resolution 78, the
main terms and conditions of the Merger are described below.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">1</TD><TD STYLE="text-align: justify">Identification of the companies involved in the transaction and a brief description of the activities
they perform</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>1.1</B></FONT></TD><TD STYLE="text-align: justify"><U>Marfrig Global Foods S.A.</U> Marfrig is a publicly traded company, registered as category &ldquo;A&rdquo;
issuer of securities with the Brazilian Securities and Exchange Commission (&ldquo;<B>CVM</B>&rdquo;) and listed on B3 S.A. &ndash; Brasil,
Bolsa, Balc&atilde;o (&ldquo;<B>B3</B>&rdquo;), and admitted for trading on the &ldquo;Novo Mercado&rdquo; B3 segment (&ldquo;<B>Novo
Mercado</B>&rdquo;), with its registered office located in the city of S&atilde;o Paulo, State of S&atilde;o Paulo, at Avenida Queiroz
Filho, No. 1,560, Block 5 (Sabi&aacute; Tower), 3rd floor, Room 301, Vila Hamburguesa, ZIP Code 05319-000, registered with the National
Registry of Legal Entities of the Ministry of Finance (&ldquo;<B>CNPJ/MF</B>&rdquo;) under No. 03.853.896/0001-40. Marfrig's corporate
purpose includes the following activities: (i) operation of slaughterhouses, including the slaughtering of cattle, horses, pigs, goats,
sheep, poultry, and buffalo, and the industrialization and commercialization of animal products and by-products, edible or otherwise,
including, but not limited to, the industrialization and commercialization of leather
products and by-products, in its own or third-party establishments; (ii) purchase, sale, distribution, representation, import, and export
of food products in general, including alcoholic and non-alcoholic beverages and others; (iii) purchase and sale of live cattle, horses,
pigs, goats, sheep, poultry, and buffalo; (iv) provision of actual labor to other companies; (v) engagement in agricultural, livestock,
and forestry activities; (vi) participation as a partner or shareholder in any commercial or civil company; (vii) distribution and commercialization
of food products in general; (viii) production, distribution, and commercialization of soaps, washing preparations, disinfectants, fabric
softeners, and other hygiene and cleaning products; (ix) cogeneration, production, and commercialization of energy and biodiesel; (x)
participation in the financial market, as well as in the carbon credit market; (xi) commercialization and production of products derived
from legumes and vegetables, including all their derivatives and substitutes, feed, preserves, canned goods, and fats; (xii) transportation
of its products and third-party products; representation and other related ventures necessary for the corporate purposes; (xiii) breeding,
rearing, and fattening of live cattle, horses, pigs, goats, sheep, poultry, and buffalo in its own and third-party establishments; (xiv)
import and export of products related to the agricultural and livestock activities, including embryos and others; (xv) provision of actual
labor to other companies; (xvi) provision of services to third parties for the breeding, care, management, fattening, and transportation
of live cattle, horses, pigs, goats, sheep, poultry, and buffalo; (xvii) technical tests and analyses; (xviii) production of pharmaceutical
and chemical products of animal origin; (xix) production of unspecified organic chemical products; and (xx) ecological restoration services.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>1.2</B></FONT></TD><TD STYLE="text-align: justify"><U>BRF S.A.</U> BRF is a publicly traded company, registered as category &ldquo;A&rdquo; issuer of securities
with the CVM, listed on B3, and admitted for trading on the Novo Mercado, with its registered office located in the city of Itaja&iacute;,
State of Santa Catarina, at Rua Jorge Tzachel, 475, Fazenda Neighborhood, ZIP Code 88301-600, registered with the CNPJ/MF under No. 01.838.723/0001-27.
BRF's corporate purpose includes the following activities: (i) industrialization, retail and wholesale commercialization, and exploitation
of food products in general, primarily those derived from animal protein and food products that use the cold chain as a support and distribution
method; (ii) industrialization and commercialization of animal feed, nutrients, and food supplements; (iii) provision of food services
in general; (iv) industrialization, refining, and commercialization of vegetable oils, fats, and dairy products; (v) engagement, conservation,
storage, ensiling, and commercialization of grains, their derivatives, and by-products; (vi) retail and wholesale commercialization of
consumption and production goods, including commercialization of equipment and vehicles for the development of its logistical activity;
(vii)&nbsp;export and import of production and consumption goods; (viii)&nbsp;provision of services of transportation, logistics and distribution
of cargo and food products in general; (ix)&nbsp;participation as a partner or shareholder in other companies, aiming at the broadest
fulfillment of its corporate purpose; (x)&nbsp;participation in projects necessary to the operation of the its business; (xi)&nbsp;industrialization,
on its own or by third-party establishments, commercialization, export and import of pharmaceutical and chemical products of animal origin;
(xii)&nbsp;production and commercialization of organic chemical products of animal origin; (xiii)&nbsp;production, distribution and export
of pharmaceutical inputs of animal origin; (xiv) intermediation and agency of services and businesses in general, except real estate;
(xv) provision of administrative services to third parties; and (xvi) provision of laboratory analysis and technical services to third
parties.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">2</TD><TD STYLE="text-align: justify">Description and purpose of the transaction</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The transaction set forth in the Plan of Merger
consists of the acquisition by Marfrig of all BRF shares not held by Marfrig on the Closing Date, in exchange for the issuance to BRF
shareholders (except Marfrig) of ordinary shares of Marfrig, in accordance with the Exchange Ratio (as defined below), resulting in the
transfer of BRF's shareholder base to Marfrig (&quot;<B>Share Incorporation</B>&quot;). Upon the completion of the Share Incorporation,
BRF will become a wholly-owned subsidiary of Marfrig.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">3</TD><TD STYLE="text-align: justify">Main benefits, costs and risks of the transaction</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>3.1</B></FONT></TD><TD STYLE="text-align: justify"><U>Benefits</U>. The Share Incorporation aims to create a global food company based on a multiprotein
platform, with a strong presence in both domestic and international markets, portfolio diversification, scale, efficiency, and sustainability,
providing significant benefits to both Companies, their shareholders, customers, suppliers, employees, and other stakeholders, generating
operational, financial, and strategic synergies.</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">Additionally, the Companies believe that the Share
Incorporation allows for the simplification and optimization of the administrative and corporate structure of the economic group to which
they belong, eliminating or reducing redundant costs, and improving or facilitating access to the capital necessary for the development
of their business plans.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 0.5in; text-align: justify">In this regard, the Companies believe that the
Share Incorporation will have significant strategic value added, driving global consolidation of their businesses and strengthening their
brands through a robust multi-protein platform, including, among others, (i) solidifying their position as a dominant power in the global
food market; (ii) strategic expansion into new markets, maximizing growth opportunities and commercial synergies, including cross-selling
initiatives; and (iii) increasing the scale and diversification of their operations, enhancing resilience and mitigating risks associated
with sector seasonality and macroeconomic variables.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 0.5in; text-align: justify">The Companies have identified potential synergies
in the context of the Share Incorporation. These synergies include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an increase in revenues and a reduction in costs estimated of R$485 million per year, resulting from the
acceleration of cross-selling opportunities, including volumes and price premiums in the Brazilian and Halal markets (brand and distribution),
and supply chain synergies (raw materials, packaging, and inputs);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a reduction in expenses estimated of R$320 million per year, resulting from the commercial and logistics
structure, the consolidation of a single operational system, and the optimization of the corporate structure; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">resulting fiscal optimization estimated of R$3 billion, net present value.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>3.2</B></FONT></TD><TD STYLE="text-align: justify"><U>Costs</U>. <FONT STYLE="line-height: 120%">It is estimated that the total costs of the Share Incorporation
will be approximately R$ 24 million, including expenses for publications, auditors, appraisers, legal and financial advisors, and other
professionals hired to assist in the Share Incorporation, not including any potential outlays incurred to obtain any third-party approvals
required for the implementation of the Share Incorporation.</FONT></TD></TR></TABLE>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>3.3</B></FONT></TD><TD STYLE="text-align: justify"><U>Risks</U></TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The management of the Companies does not foresee
any material risks for the implementation of the Share Incorporation beyond those typically associated with the Companies' daily activities
and consistent with their size and operations.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">However, it is noted that the market value of the
shares issued by Marfrig and BRF remains subject to market fluctuations through the Closing Date and, in the case of Marfrig shares, also
after the completion of the Share Incorporation, due to a series of factors outside the control of the Companies.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">Moreover, the success of the Share Incorporation
will depend, in part, on the group's ability to reduce expenses and optimize processes as a result of the simplification of its corporate
structure and consolidation of its businesses. However, there is no certainty that such cost reductions and process optimizations will
be successful. If these objectives are not achieved successfully, the expected benefits from the Share Incorporation may not fully materialize
or may take longer than anticipated to be realized.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The materialization of any of the above risks or
the partial or total failure of the growth opportunities and synergies mapped out within the scope of the Share Incorporation could adversely
impact the economic and financial situation, operational results, and the trading price of the securities issued by the Companies.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">4</TD><TD STYLE="text-align: justify">Exchange Ratio for Shares</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">As a result of the Share Incorporation, BRF shareholders
(except Marfrig) will receive 0.8521 ordinary shares of Marfrig for each 1 (one) ordinary share of BRF held on the Closing Date, in accordance
with the terms of the Plan of Merger (&quot;<B>Closing Date</B>&quot; and &quot;<B>Exchange Ratio</B>,&quot; respectively).</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The negotiation and determination of the Exchange
Ratio took into account the distribution of dividends and/or interest on own capital in the gross amount of (i) R$3,520,000,000.00 (three
billion, five hundred and twenty million reais) by BRF; and (ii) R$2,500,000,000.00 (two billion, five hundred million reais) by Marfrig,
in both cases, to be authorized following the payment of the right of withdrawal of any Dissenting Shareholders (as defined below) and
up to and including the Closing Date (collectively, &quot;<B>Permitted Distributions</B>&quot;). In this regard, any Dissenting Shareholders
who exercise their right of withdrawal shall not be entitled to receive the Permitted Distributions.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The Exchange Ratio shall be adjusted exclusively
(i) in the event of stock splits, consolidations, or share grants of either Company; and/or (ii) according to the methodology set forth
in Annex 3.1.5. of the Plan of Merger. In accordance with the methodology described in Annex 3.1.5 of the Plan of Merger, any disbursement
incurred by the Companies upon exercising the right of withdrawal will reduce the Permitted Distributions by an equivalent amount, applied
proportionally to both Companies.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The replacement of the shares issued by BRF underlying
the American Depositary Shares representing common shares issued by BRF within the scope of the Share Incorporation will be carried out
in accordance with the terms of the respective deposit agreement.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34.05pt; text-align: justify">Any fractional ordinary shares of Marfrig resulting
from the Share Incorporation will be aggregated into whole numbers and subsequently sold on the B3 spot market after the completion of
the Share Incorporation, in accordance with a communication to be timely disclosed to the market by Marfrig. The proceeds from such sales
will be made available, net of fees, to the former BRF shareholders
who are entitled to the respective fractions, proportionally to their participation in each share sold.</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">Marfrig will not issue shares in connection with
the Share Incorporation corresponding to any BRF shares that may be held in treasury, which will be canceled by BRF up to the Closing
Date.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">5</TD><TD STYLE="text-align: justify">Criteria for Determining the Exchange Ratio</TD></TR></TABLE>

<P STYLE="font: bold 10pt/120% Arial,sans-serif; margin: 14pt 0 7pt 34pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">Considering
that the Share Incorporation is a transaction involving the controlling company, Marfrig, and the controlled company, BRF, in compliance
with CVM Guidance Opinion No. 35, of September 1, 2008, the BRF Board established a special independent committee of BRF (&ldquo;</FONT>BRF
Independent Committee<FONT STYLE="font-weight: normal">&rdquo;), whose function was to negotiate the Exchange Ratio and other terms and
conditions of the transaction involving the Companies and submit its recommendation to the BRF Board. The BRF Independent Committee was
advised by Citigroup as its financial advisor, and a fairness opinion was issued by Citigroup Global Markets Inc. in connection with the
Share Incorporation.</FONT></P>

<P STYLE="font: bold 10pt/120% Arial,sans-serif; margin: 14pt 0 7pt 34pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">In
addition, the Marfrig Board established a special independent committee of Marfrig (&ldquo;</FONT>Marfrig Independent Committee<FONT STYLE="font-weight: normal">&rdquo;
and, together with the BRF Independent Committee, &ldquo;</FONT>Independent Committees<FONT STYLE="font-weight: normal">&rdquo;), which
was responsible for the initial proposal and subsequent negotiation of the Exchange Ratio with the BRF Independent Committee.</FONT></P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">In this regard, the Exchange Ratio was exhaustively
negotiated between the Independent Committees, taking into account the fair value of the Companies, as well as the assumptions described
in the Plan of Merger, and their recommendation was approved by both Independent Committees in a meeting held on May 15, 2025. In issuing
their favorable recommendation for the transaction, the Independent Committees considered, with the assistance of their external advisors,
a variety of factors, such that the Exchange Ratio was not determined based on a single criterion, but on a combination of various criteria.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">6</TD><TD STYLE="text-align: justify">Main active and passive elements that will form each portion of the assets, in case of a split-off.</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">Not applicable, given that the Share Incorporation
does not involve a split-off.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">7</TD><TD STYLE="text-align: justify">Whether the transaction has been or will be submitted for approval to Brazilian or foreign authorities</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">Not applicable.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">8</TD><TD STYLE="text-align: justify">In operations involving controlling, controlled, or commonly controlled companies, the share exchange
ratio calculated in accordance with Article 264 of Law No. 6,404/1976</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify; text-indent: 0in">Pursuant to Article 264 of the
Brazilian Corporations Law, an appraisal report was prepared containing the calculation of the Exchange Ratio of the shares held by the
non-controlling shareholders of BRF, based on the market value of the shareholders&rsquo; equity of Marfrig and BRF, evaluated in accordance
to the same criteria and as of December 31, 2024, at market prices (&ldquo;<B>Article 264 Appraisal Report</B>&rdquo;).</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify; text-indent: 0in">If the exchange ratio resulting
from the Share Incorporation were calculated based on the Article 264 Appraisal Report, 2.26148341591578 ordinary shares of Marfrig would
be delivered for each 1 (one) ordinary share of BRF held by the shareholders of BRF (excluding Marfrig).</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">9</TD><TD STYLE="text-align: justify">Applicability of the right of withdrawal and the value of the refund</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">As provided in Articles 137 and 252, paragraph
2, of the Brazilian Corporations Law, the Share Incorporation, if approved, will entitle the holders of shares issued by the Companies
to the right of withdrawal.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify">The right of withdrawal will be guaranteed to the
shareholders of each of the Companies who (i) have been holders of shares issued by Marfrig or BRF, as the case may be, uninterruptedly
from the date of disclosure of this joint material fact (inclusive) until the Closing Date; (ii) do not vote in favor of the Share Incorporation,
abstain from voting, or do not attend the Marfrig EGM or the BRF EGM, as the case may be; and (iii) expressly manifest their intention
to exercise the right of withdrawal within 30 (thirty) days from the date of publication of the minutes of the Marfrig EGM or the BRF
EGM, as the case may be (&ldquo;<B>Dissenting Shareholders</B>&rdquo;).</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>9.1</B></FONT></TD><TD STYLE="text-align: justify"><U>Dissenting Shareholders of Marfrig</U>. Pursuant to the Brazilian Corporations Law, the Dissenting
Shareholders of Marfrig will be entitled to the right of withdrawal at the value of the shareholders&rsquo; equity per share of Marfrig,
as approved by the Marfrig ordinary general meeting held on March 31, 2025, which corresponds to R$3.32 (three <I>reais</I> and thirty-two
cents) per share, without prejudice to the right to request a special balance sheet, in accordance with Article 45 of the Brazilian Corporations
Law.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>9.2</B></FONT></TD><TD STYLE="text-align: justify"><U>Dissenting Shareholders of BRF</U>. Pursuant to the Brazilian Corporations Law, the Dissenting Shareholders
of BRF shall be entitled to the right of withdrawal at the value of the shareholders&rsquo; equity per share of BRF as of December 31,
2024, as approved by the BRF ordinary general meeting held on March 31, 2025, which corresponds to R$9.43 (nine <I>reais</I> and forty-three
cents) per share, without prejudice to the right to request a special balance sheet, in accordance with Article 45 of the Brazilian Corporations
Law.</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify; text-indent: 0in">As described in item 8 above,
it is observed that the exchange ratio calculated based on the Article 264 Appraisal Report is more advantageous to the shareholders of
BRF when compared to the Exchange Ratio.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt 34pt; text-align: justify; text-indent: 0in">Therefore, the provisions of
Article 264, paragraph 3, of the Brazilian Corporations Law will apply and the Dissenting Shareholders of BRF may opt between (i) the
reimbursement value fixed in accordance with Article 45 of the Brazilian Corporations Law, that corresponds to R$9.43 (nine <I>reais</I>
and forty-three cents) per share, as mentioned above; or (ii) the shareholders&rsquo; equity per share of BRF, determined based on the
Article 264 Appraisal Report, which corresponds to R$19.89 (nineteen <I>reais</I> and eighty-nine cents.) per share.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>9.3</B></FONT></TD><TD STYLE="text-align: justify"><U>Reconsideration</U>. The Companies reserve the right to convene general meetings of the Companies to
ratify or reconsider the Share Incorporation, if they determine that the payment of the share refund price to the Dissenting Shareholders
who exercised the right of withdrawal would jeopardize the financial stability of any of the Companies, in accordance with Article 137,
paragraph 3, of the Brazilian Corporations Law.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 11pt/120% Arial,sans-serif; margin-top: 14pt; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">10</TD><TD STYLE="text-align: justify">Other relevant information</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.1</B></FONT></TD><TD STYLE="text-align: justify"><U>Corporate approvals</U>. The completion of the Share Incorporation, which will also be subject to the
satisfaction of the Condition Precedent (as defined below) and to the occurrence of the Closing Date, will depend on the performance of
the following acts, all of which are interdependent and must be coordinated to occur on the same date:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 34pt">(i)</TD><TD STYLE="text-align: justify">BRF EGM to, in this order, (a) approve the Plan of Merger; (b) approve the Share Incorporation; (c) ratify
the appointment of the appraiser responsible for preparing the c, at market value, of the BRF shares to be incorporated by Marfrig (&ldquo;<B>Share
Incorporation Appraisal Report</B>&rdquo;) and the Article 264 Appraisal Report; (d) approve the Share Incorporation Appraisal Report;
(e) approve the Article 264 Appraisal Report; and (f) authorize the BRF administrators to perform all acts necessary for the completion
of the Share Incorporation, including, without limitation, the subscription of the ordinary shares to be issued by Marfrig on behalf of
the BRF shareholders (excluding Marfrig) on the Closing Date, in accordance with Article 252, paragraph 2, of the Brazilian Corporations
Law; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 34pt"></TD><TD STYLE="width: 34pt">(ii)</TD><TD STYLE="text-align: justify">Marfrig EGM to, in this order, (a) approve the Plan of Merger; (b) approve the Share Incorporation; (c)
approve the increase in the share capital of Marfrig, the respective issuance of ordinary shares by Marfrig, as well as the consequent
amendment and consolidation of Marfrig's bylaws, with delegation to Marfrig Board of the powers to confirm the actual number of shares
to be issued by Marfrig, in the event of adjustments to the Exchange Ratio; (d) ratify the appointment of the valuation company responsible
for the preparation of the Share Incorporation Appraisal Report; (e) approve the Share Incorporation Appraisal Report; (f) approve Appraisal
Report 264; and (g) authorize the management to perform all acts necessary for the completion of the Share Incorporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.2</B></FONT></TD><TD STYLE="text-align: justify"><U>Condition Precedent</U>. From the date of execution of the Plan of Merger until the Closing Date (inclusive),
there shall be no occurrence of war, armed conflicts, natural disasters and/or other events (e.g. health emergencies; fires in manufacturing
units) that adversely and materially impact the productive capacity and/or commercialization (including export) of either Company (&quot;<B>Condition</B>&quot;).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.3</B></FONT></TD><TD STYLE="text-align: justify"><U>Closing</U>. Once the Share Incorporation is approved by the EGMs, the Companies and their respective
management shall perform all acts and measures necessary for the implementation of the Share Incorporation, including, without limitation,
the confirmation of the occurrence or the waiver of the Condition, as applicable, and the Companies shall disclose the Closing Date to
the market in accordance with applicable legislation and regulations.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.4</B></FONT></TD><TD STYLE="text-align: justify"><U>Change of Corporate Name</U>. Additionally, Marfrig informs that it has submitted to the Marfrig EGM
the proposal to approve the change of Marfrig's corporate name from &quot;Marfrig Global Foods S.A.&quot; to &quot;<B>MBRF Global Foods
Company S.A.</B>,&quot; subject to the consummation of the Share Incorporation.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.5</B></FONT></TD><TD STYLE="text-align: justify"><U>Additional Information</U>. In compliance with the provisions of Article 3 of CVM Resolution 78 and
the provisions of CVM Resolution No. 81, of March 29, 2022, the documents related to the Share Incorporation and the EGMs are or will
be, as applicable, available to the shareholders of each of the Companies at the registered office of each of the Companies, as well as
on the websites of Marfrig (ri.marfrig.com.br) or BRF (ri.brf-global.com), as the case may be, of CVM (www.gov.br/cvm) and B3 (www.b3.com.br),
and may be consulted by the shareholders of the Companies, in accordance with applicable regulations.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/120% Arial,sans-serif; margin-top: 0; margin-bottom: 7pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><FONT STYLE="font-size: 10.5pt; line-height: 120%"><B>10.6</B></FONT></TD><TD STYLE="text-align: justify"><U>Forward-Looking Statements and Projections</U>. This material fact presents projections, estimates,
expectations, and forward-looking statements of the Companies, including the anticipated effects of the Share Incorporation. These projections,
estimates, expectations, and forward-looking statements are largely based on current expectations, estimates of future projections, and
trends that affect or may affect the Companies' sectors, market shares, businesses, operations, and results. While the Companies believe
that these estimates and forward-looking statements are based on reasonable assumptions, as described above, they are subject to various
risks, uncertainties, and assumptions outside the control of the Companies, including (without limitation) the risk factors described
in items 4.1 to 4.3 of the reference form of each of the Companies, and are made based on the information currently available to the Companies.
The information presented above reflects the Company's expectations, which are subject to risks and uncertainties, and are estimated and
indicative data that do not constitute a performance promise. These expectations depend on market conditions, the economic scenario, and
the sectors in which the Companies operate. Any change in the perception or assumptions described above may result in actual outcomes
differing from the presented projections.</TD></TR></TABLE>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify">Additional information regarding the matters described
in this material fact will be promptly disclosed by the Companies in accordance with applicable legislation and regulations.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: center">S&atilde;o Paulo, May 15, 2025.</P>

<P STYLE="font: 10pt/120% Arial,sans-serif; margin: 0 0 7pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font-family: Arial,sans-serif; text-align: center; line-height: 120%"><B>MARFRIG GLOBAL FOODS S.A.</B></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font-family: Arial,sans-serif; text-align: center; line-height: 120%"><B>BRF S.A.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font-family: Arial,sans-serif; text-align: center; line-height: 120%"><B>Tang David<BR>
</B>Chief Financial Officer and Chief Investor Relations Officer</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 7pt; padding-left: 5.4pt; font-family: Arial,sans-serif; text-align: center; line-height: 120%"><B>F&aacute;bio Luis Mendes Mariano<BR>
</B>Chief Financial and Investor Relations Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt/107% Arial,sans-serif; margin: 0 0 8pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Gray 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center">&nbsp;</TD></TR><TR><TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: right; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Arial,sans-serif; margin: 0 0 8pt; text-align: left"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>brf202505156k_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 brf202505156k_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !S 1P# 2(  A$! Q$!_\0
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MW'/>OHK3-2MM7TZ"^LY!)!.H92/Y'WJJE-P)A-2+=%,EE2")Y96"1H"S,3P
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M1T8>HQ72>(M?LO#NDS7=],J!5.Q,_-(W8 =Z\3U+X5^)M+N3]D@%V@/RRP.
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M6C626FGVZ00)T5!^I]35NLZD^=W+A'E5@HHHK,L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>brf202505156k_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 brf202505156k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 +(# 2(  A$! Q$!_\0
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M&O6AF=K1110(**** "BBO.OC%XLF\.>%DM+.0QWNHLT2NIP4C ^<CWY _&@
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MAP20O;*9);5G+JR#J5)Y!'7&3FO)?#&NW'AOQ'9:K;L0T$@+J/XTZ,OXC(H
M^QZ\U\6?&;1?#UW)8V$+:G=QDJ_EN%B1@<$%N<GZ#\:M?%GQ4^A>!B;&;%QJ
M1$$4B'D(1EF'X<9[;A7@O@OP==^-M6FT^TN(H'B@,Q>4'& 0,<?[U ';3_'S
MQ#*Z"TTO3H^Q#!W)/MAA4GQ[FEDU?1%<D#[&S[.P8MSQ^ _*MOPM\#!INL07
M^M:C%<QP.'2W@0X<CD;B>V>V.?6L7]H#_D8M)_Z]&_\ 0S0!SWPS\?67@9]2
M>[L9KEKL1A#$P&T+NSG/KN'Y5Z?HOQMTS6M;LM,BTF[CDNYEA5V=<*6.,FO+
M_AK\/[;QU_:7VB_EM?LGE[?+0-NW;NN3_L_K7K7A7X.:/X9UN+57O;B]G@.Z
M%9%"JK?WB!U/I0!Z/1110(^8?&MA+IOB_5+=B^!<,Z@D_=8[A^A%8$;;9%/O
M7K_QC\/L);;788R5(\BX(['^$G]1^ KR)X^Z_E7T]"2J4E)'E^V=.KRS>ST9
M>#8Z]*>"#TJO$V^,'OT-/&<\5Y&)R^G4;:T9][A\=)13W1.ISQ5BV'WF_"JB
M[_3\ZD6\ !1!C!Y/O7B5LMQ$;\JOZ'MT<QH:1F[-[7+S,%&6.!5>2<MD+P/Y
MU 9 [<MD^IH+*!G<*Y%A*R>L']QV?6J+7QK[R>&ZN+?_ %,SI[ \?E6M9:Q>
M'YI!&ZCU7&3^%8(D0'D$CTJ=)KBZECMK:,AI&"(B<DDG %14P,YNTHV]?ZN8
MSQ%"U]SV[X=2/=Z?=WCQ*@:01K@YZ#)_F/RKM*RO#>D+H7A^STX8+1)^\([N
M>6/YDUJUZ="C&C35..R/S_%UE6KRFMF?('CBS:P\<ZW;OG(O)&!(QD,Q8?H1
M7T#\&]0M[SX<6,$,@:6T>2*9>ZL7+#]&%<C\:/ -S=7!\4:7"9<(%O8D&6XX
M$@'?C@^F ?6O)_#?BO6/"=\UUI-T8BX DC8;DD [,#_/K6QS'UMK4L,.A:A+
M<*&A2VD9U)QE=IR,U\911O-,D4:EG=@JJ!DDFO0-?^,?B'Q!HDVE2P65O%<)
MLE>%&#,.XY8XS6M\(?A[<:EJ=OXCU*$QZ?;-OMU<<SN.A _N@\Y[D?6@#4^.
M<#6?A_PO:,0QB5T) ZE505D_ +_D<M0_[![?^C$K>_:$_P"/30?]^;^25@_
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LJ4M#MA3@M4C9HHHKF-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
